Devinsky, O., Honigfeld, G. & Patin, J. (1991) Clozapinerelated seizures. Neurology, 41, 369–371.
Gerson, S. L. & Meltzer, H. (1992) Mechanisms of clozapine-induced agranulocytosis. Drug Safety, 7 (suppl. 1), 17–25.
Kane, J. M. (1992) Clinical efficacy of clozapine in treatment refractory schizophrenia: an overview. British Journal of Psychiatry, 160 (suppl. 17), 41–45.
Lieberman, J. A. & Safferman, A. Z. (1992) Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatric Quarterly, 63, 51–70.
Meltzer, H. & Okayli, G. (1995) Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. American Journal of Psychiatry, 152, 183–190.
Paton, C. & Wolfson, P. M. (1996) Is clozapine TDM therapeutic: a naturalistic study to evaluate the relationship between clozapine serum levels and clinical effect. Journal of Pharmacy Practice, 6, 371–373.
Perry, P. J., Miller, D. D., Arndt, S. V., et al (1991) Clozapine and norclozapine plasma concentrations and clinical response to treatment-refractory schizophrenic patients. American Journal of Psychiatry, 148, 231–235.
Taylor, D. & Duncan, D. (1995) The use of clozapine plasma levels in optimising therapy. Psychiatric Bulletin, 19, 753–755.
Special Hospitals Treatment Resistant Schizophrenia Research Group (1996) Schizophrenia, violence. clozapine and risperidone: a review. British Journal of Psychiatry, 169 (suppl. 31), 21–30.
Wolfson, P. M. & Paton, C. (1996) Clozapine audit: what do the patients and relatives think?
Journal of Mental Health, 5, 267–273.